Abeona Therapeutics (ABEO) Rating Lowered to Sell at ValuEngine
Abeona Therapeutics (NASDAQ:ABEO) was downgraded by equities researchers at ValuEngine from a “hold” rating to a “sell” rating in a note issued to investors on Friday.
Several other equities research analysts also recently weighed in on ABEO. Maxim Group set a $17.00 price target on Abeona Therapeutics and gave the stock a “buy” rating in a report on Wednesday, August 16th. Zacks Investment Research downgraded Abeona Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, August 16th. HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of Abeona Therapeutics in a report on Thursday, August 24th. Royal Bank Of Canada initiated coverage on Abeona Therapeutics in a report on Thursday, September 14th. They set an “outperform” rating and a $23.00 price target on the stock. Finally, Cantor Fitzgerald restated a “buy” rating and set a $21.00 price target on shares of Abeona Therapeutics in a report on Friday, October 6th. One research analyst has rated the stock with a sell rating, two have given a hold rating and nine have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $26.10.
Shares of Abeona Therapeutics (NASDAQ:ABEO) traded down $0.75 during midday trading on Friday, reaching $16.55. The company’s stock had a trading volume of 638,391 shares, compared to its average volume of 766,060. Abeona Therapeutics has a 12 month low of $4.05 and a 12 month high of $22.75.
Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings results on Wednesday, November 15th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.05. Abeona Therapeutics had a negative return on equity of 27.69% and a negative net margin of 2,946.58%. The company had revenue of $0.22 million for the quarter, compared to the consensus estimate of $0.22 million. equities analysts expect that Abeona Therapeutics will post -0.6 earnings per share for the current year.
Large investors have recently added to or reduced their stakes in the company. State of Wisconsin Investment Board acquired a new position in shares of Abeona Therapeutics during the 2nd quarter worth about $122,000. Rhumbline Advisers acquired a new position in shares of Abeona Therapeutics during the 2nd quarter worth about $190,000. Bank of New York Mellon Corp boosted its position in shares of Abeona Therapeutics by 125.8% during the 1st quarter. Bank of New York Mellon Corp now owns 41,929 shares of the biopharmaceutical company’s stock worth $210,000 after acquiring an additional 23,358 shares in the last quarter. Schwab Charles Investment Management Inc. acquired a new position in shares of Abeona Therapeutics during the 2nd quarter worth about $264,000. Finally, California State Teachers Retirement System acquired a new position in shares of Abeona Therapeutics during the 2nd quarter worth about $275,000. 41.95% of the stock is owned by institutional investors and hedge funds.
Abeona Therapeutics Company Profile
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).
Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.